Oppenheimer Cuts Teladoc Health (NYSE:TDOC) Price Target to $7.00

Teladoc Health (NYSE:TDOC) had its target price decreased by research analysts at Oppenheimer from $12.00 to $7.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the health services provider’s stock. Oppenheimer’s target price would suggest a potential upside of 35.40% from the company’s current price.

A number of other equities analysts also recently weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, February 26th. Bank of America raised shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a report on Thursday, February 26th. Canaccord Genuity Group reduced their price objective on Teladoc Health from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Zacks Research lowered Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and an average target price of $7.75.

Teladoc Health Trading Down 1.7%

Shares of TDOC opened at $5.17 on Tuesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.67 and a current ratio of 2.77. The company has a market cap of $922.33 million, a price-to-earnings ratio of -4.54 and a beta of 2.13. The stock has a fifty day moving average price of $5.95 and a two-hundred day moving average price of $7.19. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.94.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The company had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. During the same period last year, the company posted ($0.28) earnings per share. The firm’s quarterly revenue was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Analysts predict that Teladoc Health will post -1.16 EPS for the current fiscal year.

Insider Transactions at Teladoc Health

In other news, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares of the company’s stock, valued at $1,533,904.68. This represents a 7.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Fernando M. Rodrigues sold 4,209 shares of Teladoc Health stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total transaction of $31,483.32. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.58% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Several hedge funds have recently bought and sold shares of the company. Alpine Global Management LLC acquired a new position in shares of Teladoc Health in the 4th quarter valued at $187,000. Virtu Financial LLC bought a new position in Teladoc Health during the fourth quarter worth about $854,000. Corient Private Wealth LLC grew its stake in Teladoc Health by 236.6% in the fourth quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock valued at $264,000 after acquiring an additional 26,494 shares during the period. Mackenzie Financial Corp grew its stake in Teladoc Health by 38.6% in the fourth quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock valued at $1,157,000 after acquiring an additional 46,090 shares during the period. Finally, Empowered Funds LLC increased its holdings in shares of Teladoc Health by 1.9% in the fourth quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock worth $5,196,000 after acquiring an additional 14,029 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.